Revenue: As of FY2026 Q2, the actual value is USD 1.164 M, beating the estimate of USD 1 M.

EPS: As of FY2026 Q2, the actual value is USD -0.2, beating the estimate of USD -0.5.

EBIT: As of FY2026 Q2, the actual value is USD -2.571 M.

The provided reference, a Form 8-K filing, indicates that Ensysce Biosciences, Inc. issued a press release on August 13, 2026, announcing its financial results for the fiscal quarter ended June 30, 2026. However, the actual financial results, operational metrics, cash flow data, or specific forward-looking guidance are not detailed within the body of the provided text. The document only contains a general disclaimer regarding forward-looking statements, which does not include specific company outlook or guidance. Therefore, no specific financial or operational metrics, cash flow data, unique metrics, or forward-looking guidance can be extracted from this reference .